Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2014

01-08-2014 | Letter to the Editor

Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis

Authors: Helga Maurer, Peter Haas, Tobias Wengenmayer, Michael Lübbert, Justus Duyster, Robert Zeiser

Published in: Annals of Hematology | Issue 8/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
Dietrich S, Glimm H, Andrulis M et al (2012) Braf inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038–2040PubMedCrossRef
3.
Peyrade F, Re D, Ginet C et al (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a v600e mutation. Haematologica 98:e20–e22PubMedCentralPubMedCrossRef
4.
Follows G, Sims H, Bloxham D et al (2013) Rapid response of biallelic braf v600e mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161:150–153PubMedCrossRef
5.
Munoz J, Schlette E, Kurzrock R (2013) Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a braf mutation. J Clin Oncol 31:e351–e352PubMedCrossRef
6.
Robert C, Arnault JP, Mateus C (2011) Raf inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23:177–182PubMedCrossRef
7.
Zimmer L, Hillen U, Livingstone E et al (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective braf inhibition. J Clin Oncol 30:2375–2383PubMedCentralPubMedCrossRef
8.
Dietrich S, Hüllein S, Hundemer M et al (2013) Continued response off treatment after braf inhibition in refractory hairy cell leukemia. J Clin Oncol 31:e300–e303PubMedCrossRef
Metadata
Title
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis
Authors
Helga Maurer
Peter Haas
Tobias Wengenmayer
Michael Lübbert
Justus Duyster
Robert Zeiser
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1987-7

Other articles of this Issue 8/2014

Annals of Hematology 8/2014 Go to the issue

Review Article

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy

Letter to the Editor

Successful discontinuation of eculizumab therapy in a patient with aHUS

Original Article

Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma

Letter to the Editor

Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome

Erratum

Erratum to: High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia

Original Article

Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits